+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Gabapentin Market Report and Forecast 2025-2034

  • PDF Icon

    Report

  • 350 Pages
  • July 2025
  • Region: Global
  • Expert Market Research
  • ID: 6163173
The global gabapentin market size was valued at USD 2.10 Billion in 2024, driven by the increasing use of gabapentin as a pain reliever drug across the globe. The market is anticipated to grow at a CAGR of 5.00% during the forecast period of 2025-2034 to achieve a value of USD 3.42 Billion by 2034.

Gabapentin: Introduction

Gabapentin tablets, capsules, and oral solutions are used to control seizures of certain type by combining them with other medications. They are also used as a pain reliever for postherpetic neuralgia that are basically the sensations or body aches occurring after person has had a shingle attack. It is also used to endure the pain of diabetic neuropathies and hot flashes in women who are undergoing treatment for breast cancer or the ones that have had their menopause.

Global Gabapentin Market Analysis

The major factors aiding the market growth are the undergoing development of new formulation for gabapentin in order to enhance efficacy and adherence of patient in the gabapentin market. The growing evidence of research towards the use of gabapentin to reduce alcohol dependence could possibly contribute to the expansion of the market. The escalating adoption of telemedicine, exploration of combination therapies is among some other key trends propelling the global gabapentin market expansion.

Additionally, the increased off-label prescription of gabapentin for conditions such as anxiety disorders, insomnia, and fibromyalgia, among others is also driving the demand for gabapentin. Due to the increasing geriatric population and lifestyle changes, the prevalence of chronic pain conditions such as neuropathic pain, postherpetic neuralgia, and diabetic neuropathy has also increased, owing to the market growth as gabapentin is the main prescribed drug for the treatment of such conditions. Because of its well-known opioid-sparing properties, gabapentin can be used to treat pain along with less potent opioids.

Gabapentin can potentially treat several anxiety disorders such as bipolar disorder, and other mental health conditions, which is why it has gained attention in the market. The growing emphasis on mental health and the need for effective pharmacological interventions are directly contributing to the global gabapentin market development.

Global Gabapentin Market Segmentations

The report titled “Gabapentin Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:

Market Breakup by Product Type

  • Capsule
  • Tablet

Market Breakup by Application

  • Epilepsy
  • Neuropathic Pain
  • Restless Legs Syndrome

Market Breakup by Route of Administration

  • Oral
  • Parenteral
  • Intravenous

Market Breakup by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Other Distribution Channels

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Global Gabapentin Market Overview

There are several major factors that are driving the market growth such as the increasing use of gabapentin as a pain reliever drug in the market. The rising incidence of chronic pains as shingles, diabetic neuropathy, and other pains that are hard to cure with the use of basic medicines are also contributing to the market growth.

Additionally, escalating demand for generic drug development which is comparatively less expensive than the drugs that are undersigned with name of big brands is propelling the growth of the market. Some other factors driving the market growth include the affordability and availability of Gabapentin in countries that are still developing with reasonable healthcare budgets. Gabapentin is available in different form as topical gels, oral solutions, capsules, tablets, and creams, and this factor is also a major driver for the gabapentin market growth. The increase in research and development to find new applications of gabapentin and develop new formulations to enhance the efficacy is a driver owing to the market growth.

Gabapentin has also been available in generic forms, which in turn is increasing competition among generic manufacturers. This competition would probably lead to lower prices and increased availability of gabapentin, driving market growth.

Gabapentin Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • Zydus Pharmaceuticals, Inc.
  • Glenmark Pharmaceuticals Limited
  • Sun Pharmaceutical Industries Ltd.
  • Ascend Laboratories, LLC
  • Apotex Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Aurobindo Pharma.
  • Amneal Pharmaceuticals LLC.
  • Cipla
  • Pfizer Inc.

This product will be delivered within 3-5 business days.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Gabapentin Market Overview
3.1 Global Gabapentin Market Historical Value (2018-2024)
3.2 Global Gabapentin Market Forecast Value (2025-2034)
4 Global Gabapentin Market Landscape
4.1 Image Guided Surgery: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Image Guided Surgery: Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Technology
4.2.3 Analysis by Route of Administration
5 Global Gabapentin Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Gabapentin Market Segmentation
6.1 Global Gabapentin Market by Product Type
6.1.1 Market Overview
6.1.2 Capsule
6.1.3 Tablet
6.2 Global Gabapentin Market by Application
6.2.1 Market Overview
6.2.2 Epilepsy
6.2.3 Neuropathic Pain
6.2.4 Restless Legs Syndrome
6.3 Global Gabapentin Market by Route of Administration
6.3.1 Market Overview
6.3.2 Oral
6.3.3 Parenteral
6.3.4 Intravenous
6.4 Global Gabapentin Market by Distribution Channel
6.4.1 Market Overview
6.4.2 Hospital Pharmacies
6.4.3 Retail Pharmacies
6.4.4 Other Distribution Channels
6.5 Global Gabapentin Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Gabapentin Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Gabapentin Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Gabapentin Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Gabapentin Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Gabapentin Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by NIH Departments
14.7 Analysis by Recipient Organization
15 Clinical Trials Analysis
15.1 Analysis by Trial Registration Year
15.2 Analysis by Trial Status
15.3 Analysis by Trial Phase
15.4 Analysis by Therapeutic Area
15.5 Analysis by Geography
16 Funding and Investment Analysis
16.1 Analysis by Funding Instances
16.2 Analysis by Type of Funding
16.3 Analysis by Funding Amount
16.4 Analysis by Leading Players
16.5 Analysis by Leading Investors
16.6 Analysis by Geography
17 Partnership and Collaborations Analysis
17.1 Analysis by Partnership Instances
17.2 Analysis by Type of Partnership
17.3 Analysis by Leading Players
17.4 Analysis by Geography
18 Supplier Landscape
18.1 Zydus Pharmaceuticals, Inc.
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.1.5 Certifications
18.2 Glenmark Pharmaceuticals Limited
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.2.5 Certifications
18.3 Sun Pharmaceutical Industries Ltd.
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.3.5 Certifications
18.4 Ascend Laboratories, LLC
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.4.5 Certifications
18.5 Apotex Inc.
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.5.5 Certifications
18.6 Teva Pharmaceutical Industries Ltd.
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.6.5 Certifications
18.7 Aurobindo Pharma.
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.7.5 Certifications
18.8 Amneal Pharmaceuticals LLC.
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.8.5 Certifications
18.9 Cipla
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.9.5 Certifications
18.10 Pfizer Inc.
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.10.5 Certifications
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket

Companies Mentioned

  • Zydus Pharmaceuticals, Inc.
  • Glenmark Pharmaceuticals Limited
  • Sun Pharmaceutical Industries Ltd.
  • Ascend Laboratories, LLC
  • Apotex Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Aurobindo Pharma.
  • Amneal Pharmaceuticals LLC.
  • Cipla
  • Pfizer Inc.